Skip to the content

The Viracor Eurofins Difference

Viracor is committed to providing you the highest quality infectious disease test results in 24 hours.  Our experience designing complex assays along with our proven history of rapidly launching highly sensitive and specific assays in response to emerging diseases and patients’ critical needs helps you get the results you need, faster.

Molecular Assays Designed to Help You Reduce False Negatives and Under-quantification

The highly mutable nature of pathogens often proves challenging in molecular assay design. Traditional qPCR assays are designed so that a single primer and probe set targets one location within the pathogen genome. However, these single-target assays often prove inadequate to detect and quantify viral targets. Sequence polymorphisms in the assay target region can cause impaired primer or probe binding, which may result in significant under-quantification or a false negative result. To eliminate this possibility, Viracor’s qPCR assays often target two regions within the pathogen genome, utilizing unique primer and probe sets for each target site. The driving principle behind our multiple-target assay design is that when a polymorphism occurs in one assay target, the additional sets of primers and probes for the alternate target region will still detect and accurately quantify the pathogen, and thus reduces the likelihood of under-qualification or a false negative result.

Assay Refinement Helps You Account for New Strains or Mutations that Might Otherwise be Missed

At Viracor, we believe that ensuring the accuracy of each test is just as important as developing new ones, so pathogen surveillance and assay refinement is a top priority. By utilizing nucleic acid sequence databases, each qPCR assay is regularly assessed to verify that new pathogen strains or genetic polymorphisms that arise will not lead to a false negative result. If a new pathogen strain or genetic polymorphism is identified that would lead to a false-negative result, our current qPCR assay is refined and revalidated to ensure that accurate test results are always reported. 

Viracor Eurofins designs each of our assays to account for all strains, serotypes, and clinical isolates - not just the most common ones. This is especially beneficial for immunocompromised patients who may be more likely to be infected with multiple or unusual strains. For example, the Viracor Eurofins Adenovirus qPCR assay detects all known viral serotypes with equal sensitivity. Additionally, Viracor Eurofins has designed and validated each assay to ensure there is no cross reactivity with other commonly occurring pathogens. This is critically important when testing for genetically similar but clinically divergent pathogens, such as BK virus and JC virus.

 

Variety of Accepted and Validated Specimen Types Give You More Options

Not only are Viracor’s assays extremely sensitive with rapid turnaround time, but they can identify pathogens using many different types of clinical specimens, such as plasma, urine, cerebrospinal fluid, lung tissue, bone marrow aspirate, throat specimens and fecal specimens, among other fluids and tissues.  By providing you more options you can determine what is best for your patient and capture localized viral presentations.  We pay as careful attention to our extraction methodology as we do to primer and probe design. Viracor understands that the sensitivity of PCR relies heavily on the efficiency of nucleic acid extraction. Therefore, we don't employ a "one size fits all" mentality. Our extraction methods are specimen-specific, ensuring maximum nucleic acid yields to provide the most efficient, reproducible, and sensitive results.

Fast Turnaround Time When You Need It Most

Almost all assay results in the infectious disease menu are available to you within 8-12 hours after we receive the specimen. This allows you to assess the severity of infection, adjust drug therapy regimens, and make decisions faster that are critical to outcomes of the patient.

Connect with us